Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now

Johnson & Johnson stock is ending the first week of December 2025 just below record territory after a powerful year-long rally, driven by a string of earnings beats, major acquisitions in neuroscience and oncology, and fresh clinical data in bladder cancer. At the same time, the company is absorbing huge jury verdicts in talc litigation and preparing to spin off its orthopaedics business, setting up a very different J&J for the second half of the decade. Reuters+4Johnson & Johnson Investor Relations+4Johnson & Johnson Investor Relations+4

Johnson & Johnson is trading around $205–$206 per share on Wednesday, December 3, 2025, just shy of its 52‑week high of about $207.81, after a powerful rally that has lifted the stock roughly 40% this year.MarketBeat+2ChartMill+2

As of December 2, 2025, Johnson & Johnson is trading just below all‑time highs, supported by a powerful 2025 rally, a fresh European Union drug approval, a new $3.05 billion oncology acquisition, and a planned spin‑off of its orthopaedics business. Together, these moves are reshaping the investment case for JNJ as it heads into 2026.

Johnson & Johnson is closing out 2025 as one of the standout “defensive” winners in the U.S. market. The stock is trading just below a fresh 52‑week high around $205–$208 per share, giving the healthcare giant a market capitalization of roughly $500 billion.FinancialContent